Quantcast
Home > Quotes > FLXN
FLXN

Flexion Therapeutics, Inc. Common Stock Quote & Summary Data

$23.19
*  
1.39
5.66%
Get FLXN Alerts
*Delayed - data as of Feb. 16, 2018  -  Find a broker to begin trading FLXN now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 24.754 / $ 23.17
Share Volume
633,162
50 Day Avg. Daily Volume
822,904
Previous Close
$ 24.58
52 Week High / Low
$ 32.25 / $ 16.51
Market Cap
870,571,825
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
633,162
50 Day Avg. Daily Volume:
822,904

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -3.51

Trading Range

The current last sale of $23.19 is 40.46% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 24.754 $ 32.25
 Low: $ 23.17 $ 16.51

Company Description (as filed with the SEC)

Unless the content requires otherwise, references to "Flexion," "Company," "we," "our," and "us," in this Annual Report refer to Flexion Therapeutics, Inc. and our subsidiary, Flexion Securities Corporation, Inc. Overview We are a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, or OA, a type of degenerative arthritis. In May 2016, the U.S Food and Drug Administration informed us that the safety and efficacy data from the registration program for ZilrettaTM (FX006), our lead investigational product candidate, were acceptable to support the submission of a new drug application, or NDA.  ... More ...  

Risk Grade

Where does FLXN fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 24.50
Open Date:
Feb. 16, 2018
Close Price:
$ 23.19
Close Date:
Feb. 16, 2018

Consensus Recommendation

Analyst Info